News

Delian Capital led the investment round with participation from existing and new investors including OnKure management. The investment will help the company aggressively accelerate its research and development

Merck executive board member and Merck healthcare CEO Belén Garijo said: "Our collaboration with SFJ illustrates Merck KGaA, Darmstadt, Germany's increasing focus on strategic partnering in order to

Janssen Biotech is one of the Janssen Pharmaceutical Companies owned by Johnson & Johnson. BeneVir is a portfolio company within HC2’s Pansend Life Sciences subsidiary. BeneVir is currently

This is the first of what the Company expects will be a series of product acquisitions designed to generate revenue and strengthen its financial position. Vivus CEO John

The collaboration utilises both companies’ drug discovery technologies, in particular C4XD’s Taxonomy3 novel target identification platform and ETX’s Network-driven Drug Discovery (NDD) capabilities. Teams from both companies will

The new indication approved by the US Food and Drug Administration (FDA) covers diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and DLBCL. The immunocellular therapy has

The application seeks approval for KEYTRUDA in combination with pemetrexed (ALIMTA) and platinum chemotherapy (carboplatin or cisplatin) as a first-line treatment for patients with metastatic nonsquamous non-small cell

PHN is the licensor of Gleolan (aminolevulinic acid HCl (ALA)) to NXDC. The companies share an eight-year working relationship. PHN is engaged in the development of drugs that

The ORR, which was the primary objective of the STORM trial, included two complete responses (CRs) and 29 partial (PRs) or very good partial responses (VGPRs) across patients with